Patents by Inventor Evert Johannes Bunschoten
Evert Johannes Bunschoten has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10201611Abstract: The present invention relates to a method of treating or preventing estrogen-sensitive tumours in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. The estrogenic component according to the invention does not have undesirable proliferative effects on breast and/or endometrial tissue and displays sufficient estrogenicity to prevent that its administration will lead to hypoestrogenism and/or climacteric complaints.Type: GrantFiled: January 20, 2015Date of Patent: February 12, 2019Assignee: DONESTA BIOSCIENCE B.V.Inventors: Herman Jan Tijmen Coelingh Bennink, Evert Johannes Bunschoten
-
Patent number: 9561238Abstract: The present invention relates to a method of treating or preventing estrogen-suppressed tumors in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. The estrogenic component according to the invention is particularly useful in the treatment or prevention of colorectal and prostate cancer and, unlike commonly used estrogens, does not simultaneously enhance the risk of estrogen-stimulated cancers such as breast cancer.Type: GrantFiled: February 12, 2015Date of Patent: February 7, 2017Assignee: Donesta Bioscience B.V.Inventors: Herman Jan Tijmen Coelingh Bennink, Evert Johannes Bunschoten
-
Publication number: 20150150887Abstract: The present invention relates to a method of treating or preventing estrogen-suppressed tumours in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. The estrogenic component according to the invention is particularly useful in the treatment or prevention of colorectal and prostate cancer and, unlike commonly used estrogens, does not simultaneously enhance the risk of estrogen-stimulated cancers such as breast cancer.Type: ApplicationFiled: February 12, 2015Publication date: June 4, 2015Applicant: Pantarhei Bioscience B. V.Inventors: Herman Jan Tijmen COELINGH BENNINK, Evert Johannes Bunschoten
-
Patent number: 9040509Abstract: One aspect of the invention concerns a cosmetic method of treating human skin by delivering an estrogenic component to said skin. The method comprises applying to the skin a composition containing: (i) at least 5 ?g/g of an estrogenic component selected from the group consisting of substances represented by the following formula (I) in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R5, R6, R7 is a hydroxyl group; no more than 3 of R1, R2, R3, R4 are hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors; and (ii) a cosmetically acceptable vehicle. Other aspects of the invention relate to therapeutic methods of treating or preventing vaginal dryness or acne and a therapeutic method of promoting wound healing.Type: GrantFiled: January 31, 2011Date of Patent: May 26, 2015Assignee: Pantarhei Bioscience B.V.Inventors: Herman Jan Tijmen Coelingh Bennink, Evert Johannes Bunschoten, Christian Franz Holinka
-
Patent number: 9034854Abstract: The present invention relates to a method of treating or preventing estrogen-sensitive tumors in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. The estrogenic component according to the invention does not have undesirable proliferative effects on breast and/or endometrial tissue and displays sufficient estrogenicity to prevent that its administration will lead to hypoestrogenism and/or climacteric complaints.Type: GrantFiled: July 11, 2003Date of Patent: May 19, 2015Assignee: PANTARHEI BIOSCIENCE B.V.Inventors: Herman Jan Tijmen Coelingh Bennink, Evert Johannes Bunschoten
-
Publication number: 20150133413Abstract: The present invention relates to a method of treating or preventing estrogen-sensitive tumours in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. The estrogenic component according to the invention does not have undesirable proliferative effects on breast and/or endometrial tissue and displays sufficient estrogenicity to prevent that its administration will lead to hypoestrogenism and/or climacteric complaints.Type: ApplicationFiled: January 20, 2015Publication date: May 14, 2015Applicant: Pantarhei Bioscience B.V.Inventors: Herman Jan Tijmen COELINGH BENNINK, Evert Johannes BUNSCHOTEN
-
Patent number: 8987240Abstract: The present invention relates to a method of treating or preventing estrogen-suppressed tumors in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula (I) in which formula R1, R2, R3, R4, independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. The estrogenic component according to the invention is particularly useful in the treatment or prevention of colorectal and prostate cancer and, unlike commonly used estrogens, does not simultaneously enhance the risk of estrogen-stimulated cancers such as breast cancer.Type: GrantFiled: October 23, 2003Date of Patent: March 24, 2015Assignee: Pantarhei Bioscience B.V.Inventors: Herman Jan Tijmen Coelingh Bennink, Evert Johannes Bunschoten
-
Patent number: 8048869Abstract: One aspect of the invention is concerned with a method of hormone replacement therapy, which method comprises administering to a person in need of such a therapy an effective amount of an estrogenic component selected from the group consisting of: substances represented by the formula in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alokxy group with 1-5 carbon atoms; each of R5, R6, R7 is a hydroxyl group; and no more than 3 of R1, R2, R3, R4 are hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method, and mixtures thereof; said composition containing virtually no progestogen or anti-progestin. Another aspect of the invention relates to a drug delivery system for enteral or parenteral administration that contains at least 1 ?g of the aforementioned estrogenic component and virtually no progestogen or anti-progestin.Type: GrantFiled: May 17, 2002Date of Patent: November 1, 2011Assignee: Pantarhei Bioscience B.V.Inventors: Evert Johannes Bunschoten, Herman Jan Tijmen Coelingh Bennink, Christian Franz Holinka
-
Patent number: 8026228Abstract: One aspect of the present invention relates to a method of hormone replacement in mammals, which method comprises the oral administration of an estrogenic component and a progestogenic component to a mammal in an effective amount to prevent or treat symptoms of hypoestrogenism, wherein the estrogenic component is selected from the group consisting of substances represented by the above formula in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R5, R6, R7 is a hydroxyl group; and no more than 3 of R1, R2, R3, R4 are hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors.Type: GrantFiled: May 23, 2002Date of Patent: September 27, 2011Assignee: Pantarhei Bioscience B.V.Inventors: Herman Jan Tijmen Coelingh Bennink, Evert Johannes Bunschoten, Christian Franz Holinka
-
Publication number: 20110160173Abstract: One aspect of the invention concerns a cosmetic method of treating human skin by delivering an estrogenic component to said skin. The method comprises applying to the skin a composition containing: (i) at least 5 ?g/g of an estrogenic component selected from the group consisting of substances represented by the following formula (I) in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R5, R6, R7 is a hydroxyl group; no more than 3 of R1, R2, R3, R4 are hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors; and (ii) a cosmetically acceptable vehicle. Other aspects of the invention relate to therapeutic methods of treating or preventing vaginal dryness or acne and a therapeutic method of promoting wound healing.Type: ApplicationFiled: January 31, 2011Publication date: June 30, 2011Applicant: PANTARHEI BIOSCIENCE B.V.Inventors: Herman Jan Tijmen Coelingh Bennink, Evert Johannes Bunschoten, Christian Franz Holinka
-
Patent number: 7943602Abstract: The invention relates to pharmaceutical dosage units for oral, transmucosal or transdermal administration containing 15- or 16-substituted testosterone analogues, as well as to therapeutic methods that employ these testosterone analogues. More particularly, the invention is concerned with such pharmaceutical dosage units containing at least 10 ?g of an androgenic steroid selected from the group consisting of 15-hydroxytestosterones, 16-hydroxytestosterones, precursors thereof and mixtures of these hydroxytestosterones and/or their precursors; and a pharmaceutically acceptable excipient. The term “15-hydroxytestosterones” encompasses both 15?-hydroxytestosterone (15?, 17?-dihydroxy-4-androsten-3-one) and 15?-hydroxytestosterone (15?, 17?-dihydroxy-4-androsten-3-one). Similarly, the term “16-hydroxytestosterones” encompasses both 16?-hydroxytestosterone hydroxytestosterone (16?, 17?-dihydroxy-4-androsten-3-one) and 16?-hydroxytestosterone (16?, 17?-dihydroxy-4-androsten-3-one).Type: GrantFiled: September 5, 2003Date of Patent: May 17, 2011Assignee: Pantarhei Bioscience B.V.Inventors: Evert Johannes Bunschoten, Herman Jan Tijmen Coelingh Bennink, René Frank Van Der Linden
-
Patent number: 7943604Abstract: The invention relates to cosmetic methods of treating human skin. The method includes applying to the skin a composition containing an estrogenic component and a cosmetically acceptable vehicle. Other aspects of the invention relate to therapeutic methods of treating or preventing vaginal dryness or acne and a therapeutic method of promoting wound healing. Another aspect relates to a skin care composition comprising the aforementioned estrogenic component and a cosmetically acceptable vehicle.Type: GrantFiled: June 11, 2003Date of Patent: May 17, 2011Assignee: Pantarhei Bioscience B.V.Inventors: Herman Jan Tijmen Coelingh Bennink, Evert Johannes Bunschoten, Christian Franz Holinka
-
Patent number: 7923440Abstract: A method of treating or preventing an immune mediated disorder in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula: in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R5, R6, R7 is a hydroxyl group; no more than 3 of R1, R2, R3, R4 are hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. Another aspect of the invention relates to a pharmaceutical formulation comprising the aforementioned estrogenic component, an immunotherapeutic agent and a pharmaceutically acceptable excipient.Type: GrantFiled: June 11, 2003Date of Patent: April 12, 2011Assignee: Pantarhei Bioscience B.V.Inventors: Evert Johannes Bunschoten, Herman Jan Tijmen Coelingh Bennink, Christian Franz Holinka
-
Patent number: 7871995Abstract: A method of contraception in mammalian females, which method comprises the parenteral or rectal administration of an estrogenic component and a progestogenic component to a female of childbearing capability in an amount effective to inhibit ovulation, wherein the estrogenic component is selected from the group consisting of substances represented by the following formula (1) in which R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R5, R6, R7 is a hydroxyl group; and no more than 3 of R1, R2, R3, R4 are hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors.Type: GrantFiled: May 23, 2002Date of Patent: January 18, 2011Assignee: Pantarhei Bioscience B.V.Inventors: Evert Johannes Bunschoten, Herman Jan Tijmen Coelingh Bennink, Christian Franz Holinka
-
Patent number: 7815912Abstract: One aspect of the present invention is concerned with a method of controlled ovarian hyperstimulation in a mammalian female, said method comprising the co-administration to said female of —a substance having follicle stimulating hormone activity (FSH substance) in an amount effective to stimulate multiple follicular development; —gonadotropin releasing hormone (GnRH) antagonist in an amount equivalent to a daily subcutaneous dose of at least 0.5 mg ganirelix to prevent a premature LH-surge; and —a LH substance in an amount effective to prevent or suppress symptoms of luteinising hormone (LH) deficiency resulting from the administration of the GnRH antagonist; followed by administering a meiosis and luteinisation inducing substance (ML substance) in an amount effective to stimulate resumption of meiosis and luteinisation, and wherein the LH substance is not obtained from the urine of human females.Type: GrantFiled: June 6, 2003Date of Patent: October 19, 2010Assignee: Ares Trading, S.A.Inventors: Evert Johannes Bunschoten, Herman Jan Tijmen Coelingh Bennink
-
Patent number: 7732430Abstract: A method of contraception in mammalian females, which method comprises the oral administration of an estrogenic component and a progestogenic component to a female of childbearing capability in an amount effective to inhibit ovulation, wherein the estrogenic component is selected from the group consisting of substances represented by the following formula (1) in which R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R5, R6, R7 is a hydroxyl group; and no more than 3 of R1, R2, R3, R4 are hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. Another aspect of the invention concerns a pharmaceutical kit comprising oral dosage units that contain the aforementioned estrogenic component and/or a progestogenic component.Type: GrantFiled: May 23, 2002Date of Patent: June 8, 2010Assignee: Pantarhei Bioscience B.V.Inventors: Evert Johannes Bunschoten, Herman Jan Tijmen Coelingh Bennink, Christian Franz Holinka
-
Patent number: 7723320Abstract: Disclosed is a method of increasing libido in a woman, said method comprising administering to said woman an effective amount of an estrogenic component selected from the group consisting of: substances represented by the following formula (I) in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R5, R6, R7 is a hydroxyl group; no more than 3 of R1, R2, R3, R4 are hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors.Type: GrantFiled: May 17, 2002Date of Patent: May 25, 2010Assignee: Pantarhei Bioscience B.V.Inventors: Evert Johannes Bunschoten, Herman Jan Tijmen Coelingh Bennink, Christian Franz Holinka
-
Publication number: 20040198710Abstract: A method of contraception in mammalian females, which method comprises the oral administration of an estrogenic component and a progestogenic component to a female of childbearing capability in an amount effective to inhibit ovulation, wherein the estrogenic component is selected from the group consisting of substances represented by the following formula (1) 1Type: ApplicationFiled: May 25, 2004Publication date: October 7, 2004Inventors: Evert Johannes Bunschoten, Hermann Jan Tijmen Coelingh Bennink, Christian Franz Holinka
-
Publication number: 20040198671Abstract: One aspect of the invention is concerned with a method of hormone replacement therapy, which method comprises administering to a person in need of such a therapy an effective amount of an estrogenic component selected from the group consisting of: substances represented by the formula (I) in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alokxy group with 1-5 carbon atoms; each of R5, R6, R7 is a hydroxyl group; and no more than 3 of R1, R2, R3, R4 are hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures thereof; said composition containing virtually no progestogen or anti-progestin. Another aspect of the invention relates to a drug delivery system for enteral or parenteral administration that contains at least 1 &mgr;g of the aforementioned estrogenic component and virtually no progestogen or anti-progestin.Type: ApplicationFiled: May 25, 2004Publication date: October 7, 2004Inventors: Evert Johannes Bunschoten, Herman Jan Tijmen Coelingh Bennink, Christian Franz Holinka
-
Publication number: 20040192620Abstract: A method of contraception in mammalian females, which method comprises the parenteral or rectal administration of an estrogenic component and a progestogenic component to a female of childbearing capability in an amount effective to inhibit ovulation, wherein the estrogenic component is selected from the group consisting of substances represented by the following formula (1) 1Type: ApplicationFiled: May 25, 2004Publication date: September 30, 2004Inventors: Evert Johannes Bunschoten, Herman Jan Tijmen Coelingh Bennink, Christian Franz Holinka